{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:02:38Z","timestamp":1784347358229,"version":"3.55.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.japh.2022.10.020","type":"journal-article","created":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T12:13:59Z","timestamp":1666440839000},"page":"389-395.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of a statewide community pharmacy approach to opioid harm reduction"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3165-1618","authenticated-orcid":false,"given":"Scott M.","family":"Sexton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4593-5016","authenticated-orcid":false,"given":"Macary Weck","family":"Marciniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ouita","family":"Gatton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10324","key":"10.1016\/j.japh.2022.10.020_bib3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0140-6736(22)00200-8","article-title":"Managing the opioid crisis in North America and beyond","volume":"399","author":"The Lancet","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.japh.2022.10.020_bib4","doi-asserted-by":"crossref","unstructured":"Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016 [published correction appears in MMWR Recomm Rep. 2016;65(11):295]. MMWR Recomm Rep. 2016;65(1):1\u201349.","DOI":"10.15585\/mmwr.rr6501e1er"},{"issue":"31","key":"10.1016\/j.japh.2022.10.020_bib6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.15585\/mmwr.mm6731a2","article-title":"Naloxone administration frequency during emergency medical service events - United States, 2012-2016","volume":"67","author":"Cash","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4S","key":"10.1016\/j.japh.2022.10.020_bib11","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.japh.2018.04.025","article-title":"Identifying barriers to dispensing naloxone: a survey of community pharmacists in North Carolina","volume":"58","author":"Rudolph","year":"2018","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"4S","key":"10.1016\/j.japh.2022.10.020_bib12","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.japh.2019.03.015","article-title":"A standardized team-based approach for identifying naloxone-eligible patients in a grocery store pharmacy","volume":"59","author":"Sexton","year":"2019","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"4","key":"10.1016\/j.japh.2022.10.020_bib13","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/j.japh.2021.03.004","article-title":"Examining nonprescription syringe sales in Massachusetts and Rhode Island community pharmacies","volume":"61","author":"Green","year":"2021","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2022.10.020_bib14","author":"Kokosky"},{"issue":"5","key":"10.1016\/j.japh.2022.10.020_bib16","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.japh.2022.03.015","article-title":"Pharmacy naloxone codispensing: a mixed methods study of practices and perspectives under a statewide standing order program","volume":"62","author":"Pollini","year":"2022","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"4S","key":"10.1016\/j.japh.2022.10.020_bib17","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1016\/j.japh.2020.12.007","article-title":"Impact of pharmacist counseling to enhance the accessibility of naloxone nasal spray to patients in a community pharmacy setting","volume":"61","author":"Napoli","year":"2021","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2022.10.020_bib19","first-page":"153","article-title":"The MEDD myth: the impact of pseudoscience on pain research and prescribing-guideline development","volume":"9","author":"Fudin","year":"2016","journal-title":"J\u00a0Pain Res"},{"issue":"1","key":"10.1016\/j.japh.2022.10.020_bib20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/pm\/pnx009","article-title":"Validation of a screening risk index for serious prescription opioid-induced respiratory depression or overdose in a US commercial health plan claims database","volume":"19","author":"Zedler","year":"2018","journal-title":"Pain Med"},{"issue":"2","key":"10.1016\/j.japh.2022.10.020_bib21","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1016\/j.japh.2020.10.010","article-title":"Pharmacist counseling when dispensing naloxone by standing order: a secret shopper study of 4 chain pharmacies","volume":"61","author":"Contreras","year":"2021","journal-title":"J\u00a0Am Pharm Assoc (2003)"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122003648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122003648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:51:21Z","timestamp":1761544281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319122003648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1544319122003648"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2022.10.020","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of a statewide community pharmacy approach to opioid harm reduction","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2022.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}